MarketWatch Article RatingAurinia Pharmaceuticals Partner Files NDA in Japan for Voclosporin
- Bias Rating
-16% Somewhat Liberal
- Reliability
N/AN/A
- Policy Leaning
-16% Somewhat Liberal
- Politician Portrayal
N/A
Continue For Free
Create your free account to see the in-depth bias analytics and more.
Continue
Continue
By creating an account, you agree to our Terms and Privacy Policy, and subscribe to email updates. Already a member: Log inBias Score Analysis
The A.I. bias rating includes policy and politician portrayal leanings based on the author’s tone found in the article using machine learning. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral.
Sentiments
N/A
- Liberal
| Sentence | Sentiment | Bias |
|---|---|---|
Unlock this feature by upgrading to the Pro plan. | ||
Reliability Score Analysis
Policy Leaning Analysis
Politician Portrayal Analysis
Bias Meter
Extremely
Liberal
Very
Liberal
Moderately
Liberal
Somewhat Liberal
Center
Somewhat Conservative
Moderately
Conservative
Very
Conservative
Extremely
Conservative
-100%
Liberal
100%
Conservative
Contributing sentiments towards policy:
56% : Aurinia and Otsuka entered a collaboration and licensing agreement in December 2020 for the development and commercialization of voclosporin for the treatment of LN in the EU, Japan, the U.K., Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine.53% : By Chris WackAurinia Pharmaceuticals said Monday that collaboration partner Otsuka Pharmaceutical filed a new drug application for voclosporin for the treatment of lupus nephritis with the Japanese Ministry of Health, Labor and Welfare.
*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization.